Pharmacy Benefits Consulting
At Blue & Co., LLC we are uncommonly independent with a unique and customized approach to find clients the best solution based solely on their goals and objectives and not our sales or revenue goals.
Our team is comprised of pharmacists who have been exposed to all sides of the pharmacy supply chain and work to bring that unique perspective to our clients. Our independent approach allows us to work with all PBMs, both big and small, to find the best solution for the client and their employees.
Meet Our Pharmacy Benefits Expert
Chad Downing RPH,340B ACE, Senior Pharmacy Consultant
Chad Downing is a Senior Pharmacy Consultant with Blue & Co., specializing in pharmacy reimbursements and operations performance. Throughout his 20-year career as a healthcare and pharmacy executive, he has been recognized as a proven leader in operational and financial performance.
Chad earned his Bachelor of Science degree in pharmacy from Ohio Northern University. He obtained his EMBA from the Quantic School of Business and Technology. He maintains active pharmacy licenses in Illinois, Indiana, Kentucky and Ohio. Six Sigma Greenbelt certified. He holds an Apexus Advanced 340B Operations Certificate.
Great news for 340B Hospitals affected by COVID-19. On March 15, 2022, President Biden signed into law the $1.5 trillion Consolidated Appropriations Acts, 2022. This bill allows Hospitals that have lost eligibility due to a decrease in their Medicare disproportionate share (DSH) percentage as a result of the COVID-19 public health emergency to regain access […]
The 340B Program has seen a lot of changes in 2021. Join Blue & Co.’s Apexus Advanced 340B Experts for a webinar on Thursday, July 15 at 12:00 p.m. In this webinar, Jason Prokopik and Chad Downing will be covering some of the current 340B trends and provide updates from recent HRSA Audits that may […]
After months of pharmaceutical manufacturers placing restrictions on the 340B Program to both contract pharmacies and covered entities, HRSA sent letters to six pharmaceutical manufacturers stating they violated the 340B Statute. The HRSA Acting Administrator declared these pharmaceutical manufacturers violated the 340B statue by placing restrictions on the 340B Program pricing at both contract pharmacy […]
Connect with our team.
To learn more about our services and areas of expertise, send us a message.